Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
Date:10/31/2007

NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation (Amex: CVM). The full 56-page report can be found at http://www.crystalra.com.

CEL-SCI Corporation develops immune-based cancer and infectious disease therapies. Its primary product candidate is Multikine(R), a next-generation, comprehensive immunotherapy that targets treatment-naive, newly diagnosed head and neck cancer. Multikine(R) is a mixture of biologically active natural cytokines designed to closely mimic the natural immune system.

Differing from other immunotherapies, Multikine(R) has the following attributes: (1) multitargeted-it activates multiple cellular components of the immune system to fight cancer; (2) administered as a first-line therapy before the patient receives surgery, chemotherapy, or radiotherapy, which is when the immune system is strongest; (3) kills roughly 50% of tumor cells before the standard of care is begun; (4) renders the residual live cancer cells that survive treatment more susceptible to the effects of radiation and chemotherapy, thereby potentially enhancing these treatments; and (5) is shown to be safe and well tolerated in Phase I and II clinical trials. In over 200 patients treated in CEL-SCI's trials, no severe side effects associated with Multikine(R) were reported.

Multikine(R) is now ready for a Phase III clinical trial for advanced primary head and neck cancer. In Phase III, CEL-SCI intends to administer Multikine(R) prior to the currently accepted and routinely used first-line standard of care treatment-surgery followed by radiation/chemotherapy. The Company hopes to show that Multikine(R) plus the standard of care increases patients' overall survival. CEL-SCI believes that a positive Phase III outcome could enable Multikine(R) to be routinely included as part of the standard of care for all advanced primary head and neck cancer patients. Multikine(R) may also have applications in melanoma and breast, skin, bladder, and cervical cancer.

Also in CEL-SCI's pipeline are two other platforms, a Ligand Epitope Antigen Presentation System (L.E.A.P.S.)(TM) and Antigen-Directed Apoptosis (AdapT), with a second product candidate, CEL-1000. CEL-1000, derived from L.E.A.P.S.(TM), is poised for trials as a potential adjuvant to boost vaccine immunogenicity for viral encephalitis, herpes simplex, malaria, hepatitis B, and the avian flu.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of thirty-five thousand U.S. dollars and two hundred thousand options/warrants to purchase CEL-SCI stock for its services in creating the base report, for updates, and for printing.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including: limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-K, 10-Q, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Apollos human proteins boost stem cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):